High mortality of COVID-19 associated mucormycosis in France: a nationwide retrospective study

We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus 95% in India), hematological malignancies (35% versus 1%), anatomical sites (53% lung versus >80% rhino-orbito-cerebral) and prognosis (>80% mortality versus <50%).

[1]  J. Perfect,et al.  ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries , 2021, Mycoses.

[2]  E. Kuijper,et al.  Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3]  J. Perfect,et al.  The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries , 2021 .

[4]  D. Kontoyiannis,et al.  When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis , 2021, Journal of fungi.

[5]  L. Millon,et al.  Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient , 2021, Infectious Diseases Now.

[6]  P. Le Pape,et al.  High Prevalence of Fungal Infections in Mechanically Ventilated COVID-19 Patients in the ICU: The French Multicenter MYCOVID Study , 2021, SSRN Electronic Journal.

[7]  J. Perfect,et al.  Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance , 2020, The Lancet Infectious Diseases.

[8]  J. Perfect,et al.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  F. Grenouillet,et al.  Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  T. Mitchell,et al.  A dynamic relationship between mucosal T helper type 17 and regulatory T-cell populations in nasopharynx evolves with age and associates with the clearance of pneumococcal carriage in humans. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  V. Rickerts,et al.  PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue , 2005, Journal of Clinical Pathology.